Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
Part of Cancer clinical trials.
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a BRCA1 or BRCA2 gene mutation (inherited from a parent).
- Your breast cancer is HER2-negative (confirmed by a biopsy).
- Your tumor is at least 1 cm in size, or you have inflammatory breast cancer with a measurable lesion.
- You have not had any prior treatment for this breast cancer (like chemotherapy, radiation, or targeted therapy).
- You have not received a PD-1/PD-L1 or CTLA-4 inhibitor before (drugs like Keytruda or Yervoy).
- You have not taken a PARP inhibitor (like Lynparza) before, unless it was for ovarian cancer and completed more than 5 years ago with no recurrence.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
This trial tests the PARP inhibitor fluzoparib as a maintenance treatment for women with advanced triple-negative breast cancer whose disease responded or stabilized after platinum-based chemotherapy. The goal is to see if taking fluzoparib daily can delay cancer growth.
This trial tests a combination of two drugs, camrelizumab (an immunotherapy) and fluzoparib (a PARP inhibitor), for people with a specific type of endometrial cancer that has a TP53 gene mutation. It may offer a new option for advanced or recurrent disease after limited prior treatment.
This trial tests a combination of three drugs (Fluzoparib, Camrelizumab, and Temozolomide) for people with advanced melanoma that has spread or cannot be removed by surgery. It is for those who have a specific genetic change (HR or SF3B1 mutation) and have not been treated with a PARP inhibitor before.
This trial tests a combination of medications given before surgery (neoadjuvant therapy) for early breast cancer. It is designed for tumors with certain “DNA repair” gene mutations and aims to improve treatment results while shrinking or controlling the cancer.
This trial tests whether the drug fluzoparib (a type of PARP inhibitor) can help prevent breast cancer from coming back after surgery. It is for people who have specific changes in their genes (called germline HRR mutations) and who had a high risk of recurrence based on their tumor type and response to earlier treatment.
Hear when a new Germline BRCA-mutated HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.